Literature DB >> 8739210

Benextramine acts as an irreversible noncompetitive antagonist of U46619-mediated contraction of the rat small mesenteric artery.

P H Van der Graaf1, W B Stam, P R Saxena.   

Abstract

We have studied the effects of benextramine on the U46619 (11 alpha,9 alpha-epoxymethano-15S-hydroxy-prosta-5Z,13E-dienoic acid)-mediated contraction of the rat isolated small mesenteric artery. U46619 (10 nM-10 microM) produced a concentration-dependent contraction of the small mesenteric artery. The selective prostanoid TP receptor antagonist, SQ 30,741 ([1S-[1 alpha,2 alpha(5Z),3 alpha,4 alpha]]-7- [[[[[(oxaheptyl)amino]acetyl]amino]-methyl]-7-oxabicyclo[2.2.1]hep t-2-yl]-5- heptenoic acid; 1 microM), produced a parallel, rightward shift of the U46619 curve with an associated pA2 value of 7.43 +/- 0.09. Treatment of tissues with 100 microM benextramine depressed the maximum response to U46619 in a time-dependent manner. However, neither SQ 30,741 (10 microM) nor U46619 (10 microM) incubation significantly protected against this effect. Thus, benextramine acts as an irreversible noncompetitive antagonist of U46619. The mechanism of this action is not yet clear.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8739210     DOI: 10.1016/0014-2999(96)00040-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  1 in total

1.  Potent, long-acting cyclopentane-1,3-Dione thromboxane (A2)-receptor antagonists.

Authors:  Xiaozhao Wang; Li Liu; Longchuan Huang; Katie Herbst-Robinson; Anne-Sophie Cornec; Michael J James; Shimpei Sugiyama; Marcella Bassetto; Andrea Brancale; John Q Trojanowski; Virginia M-Y Lee; Amos B Smith; Kurt R Brunden; Carlo Ballatore
Journal:  ACS Med Chem Lett       Date:  2014-07-24       Impact factor: 4.345

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.